Reaktionsgleichung
[C:1]([O:18][CH:19]([CH2:36][CH2:37][CH2:38][CH2:39][CH2:40][CH2:41][CH2:42][CH2:43][CH2:44][CH2:45][CH2:46][CH2:47][CH2:48][CH2:49][CH3:50])[CH2:20][C:21]([NH:23][CH2:24][CH2:25][C:26]([NH:28][C@H:29]([C:33](O)=[O:34])[C@@H:30]([CH3:32])[OH:31])=[O:27])=[O:22])(=[O:17])[CH2:2][CH2:3][CH2:4][CH2:5][CH2:6][CH2:7][CH2:8][CH2:9][CH2:10][CH2:11][CH2:12][CH2:13][CH2:14][CH2:15][CH3:16].[NH2:51][C@H:52]([C:65]([O:67][CH2:68][C:69]1[CH:74]=[CH:73][CH:72]=[CH:71][CH:70]=1)=[O:66])[CH2:53][CH2:54][C:55]([O:57][CH2:58][C:59]1[CH:64]=[CH:63][CH:62]=[CH:61][CH:60]=1)=[O:56]>>[C:1]([O:18][CH:19]([CH2:36][CH2:37][CH2:38][CH2:39][CH2:40][CH2:41][CH2:42][CH2:43][CH2:44][CH2:45][CH2:46][CH2:47][CH2:48][CH2:49][CH3:50])[CH2:20][C:21]([NH:23][CH2:24][CH2:25][C:26]([NH:28][C@H:29]([C:33]([NH:51][C@H:52]([C:65]([O:67][CH2:68][C:69]1[CH:70]=[CH:71][CH:72]=[CH:73][CH:74]=1)=[O:66])[CH2:53][CH2:54][C:55]([O:57][CH2:58][C:59]1[CH:64]=[CH:63][CH:62]=[CH:61][CH:60]=1)=[O:56])=[O:34])[C@@H:30]([CH3:32])[OH:31])=[O:27])=[O:22])(=[O:17])[CH2:2][CH2:3][CH2:4][CH2:5][CH2:6][CH2:7][CH2:8][CH2:9][CH2:10][CH2:11][CH2:12][CH2:13][CH2:14][CH2:15][CH3:16]Komponenten
3
Versuchsvorschrift
Starting from N-[N-(3-hexadecanoyloxyoctadecanoyl)-β-alanyl]-L-threonine (450 mg) prepared by the method of Preparation B-4 and dibenzyl L-glutamate (210 mg), dibenzyl N-[N-[N-(3-hexadecanoyloxyoctadecanoyl)-β-alanyl]-L-threonyl]-L-glutamate (250 mg) was obtained as crystals according to a similar manner to that of Example 2.
Quellen und Nachweise
- ORD-Eintrag
- ord-2925fb08182a40fab31ec394d5cdcec6
- Quelldatensatz
- uspto-grants-1987_02
- Patentnummer
- US04643990
Verknüpfte Notizen
Wird geladen…